

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)



(10) International Publication Number
WO 2020/132091 A2

(51) International Patent Classification:

C07K 16/08 (2006.01) A61K 39/395 (2006.01)
C07K 16/10 (2006.01) A61P 31/14 (2006.01)
A61K 31/522 (2006.01) A61P 31/20 (2006.01)

(21) International Application Number:

PCT/US2019/067216

(22) International Filing Date:

18 December 2019 (18.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/782,274 19 December 2018 (19.12.2018) US
62/860,085 11 June 2019 (11.06.2019) US

(71) Applicant: HUMABS BIOMED SA [CH/CH]; Via dei
Gaggini 3, 6500 Bellinzona (CH).

(72) Inventor: CORTI, Davide; c/o Humabs BioMed SA, Via
dei Gaggini 3, 6500 Bellinzona (CH).

(74) Agent: MORGAN, John, A. et al.; Seed Intellectual Prop-
erty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seat-
tle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF

Genotype	EC ₅₀ (ng/ml)
A	2.34
B	2.22
C	0.92
D	1.10
E	1.12
F	1.93
G	1.43
H	1.93

FIG. 4

(57) Abstract: The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*